Dupilumab Provides Meaningful Clinical Responses in Harlequin Ichthyosis ( <i>ABCA12</i> ‐ <scp>nEDD</scp> ): A Report of Two Cases
Harlequin ichthyosis (HI) is a rare epidermal differentiation disorder characterized by thick hyperkeratotic plates, fissuring, and high neonatal morbidity. Long-term management remains challenging. We report two children with genetically confirmed HI who demonstrated meaningful improvement in pruritus, erythema, scaling, and overall well-being following dupilumab therapy, suggesting a potential role for IL-4/IL-13 blockade as an adjunct or alternative treatment in HI.
Authors
- Minu Jose Chiramel (ORCID: https://orcid.org/0000-0003-3078-1146)
- Rebecca Levy (ORCID: https://orcid.org/0000-0002-5407-3972)
- Elaine Siegfried
- Cynthia Chen (ORCID: https://orcid.org/0000-0002-0100-1801)
Institutions
- Washington University in St. Louis (US)
- Hospital for Sick Children (CA)
- Cardinal Glennon Children’s Medical Center (US)
Publication Details
- Journal
- Pediatric Dermatology
- Published
- 2026-07-27
- DOI
- https://doi.org/10.1111/pde.70327
- Primary Topic
- Skin and Cellular Biology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00